Zentalis price target lowered to $20 from $25 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zentalis to $20 from $25 and keeps an Outperform rating on the shares following the Q2 update. The fir m says it does not have any new insights or timelines on removing azenosertib’s clinical hold, “although it obviously remains the main focus for the company at this time.” The analyst is looking forward to seeing updated data from the Phase 1/2 trial later this year and believes it could better showcase the risk-to-benefit ratio for the drug. Opco dropped the price to reflect the discontinuation of the acute myeloid leukemia program.